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Prior to 1974, the Tuskegee Syphilis experiments, expansive use of the HeLa cells, and
other blatant instances of research abuse pervaded the medical research field. Ongoing
challenges to informed consent, privacy and data-sharing will influence the stories that
research participants today share with future generations. This has significant implications
for the advancement of genomic science, and the public’s perception of genomic research.
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INTRODUCTION
Personalized genomic medicine (PGM)—medical care that is tai-
lored to individuals based on their genetic makeup—has the
potential to revolutionize the way providers diagnose and treat
patients. By testing patients for clinically validated pharmacoge-
nomic biomarkers, for instance, physicians will be able to tailor
drug selection, dosage levels, and treatment duration in ways that
avoid adverse drug reactions (Ramos et al., 2013). Inmany clinics,
physicians are already utilizing this technology.
Various bottlenecks and rate-limiting research policies, how-
ever, are preventing medical providers and patients from realizing
the full potential of PGM (Ramos and Rotimi, 2009; Ramos
et al., 2012). Insufficient enrollment of ethnically diverse pop-
ulations in genomic research and the use of vague racial and
ethnic categories to describe research participants are examples
of widespread practices that have led to knowledge gaps in PGM
(Lee, 2009; Rotimi and Jorde, 2010; Ramos et al., 2013). This has
extensive implications for scientists as well as patients, because
knowledge of the penetrance and significance of key genetic
markers will remain limited until large genomic datasets from
diverse populations are developed and explored for the benefit
of patients globally (Ramos et al., 2012, 2013)—causing frus-
tration among investigators as well as clinicians who struggle to
understand the clinical utility of certain genetic tests in diverse
populations.
Fortunately, scientists see the urgency for reform, and have the
advanced digital tools and sequencing technologies to develop
and analyze datasets that are more representative of the global
population. Further, because of the scientific value of large
genomic data-sets, prevailing regulations and policies favor a
collaborative research environment that encourages data-sharing
across international jurisdictions. These advances are not without
consequence, of course, and the future impact of the unprece-
dented data-sharing and storing that is set to take place in
the coming years intensifies longstanding challenges related to
informational privacy and public expectations about benefit shar-
ing and control over biomedical samples.
A recent NIH data-agreement with the family of Henrietta
Lacks, whose whole genome sequence was published on the
world-wide-web without her relatives’ consent and then removed
in response to staunch public disapproval, provides an example of
how innovation and communication can help bridge the cultural,
legal, and ethical divides between researchers located in one envi-
ronment and the original owners of the samples and data located
in different states, countries, and regions.
As we move forward into the future and into the era of “big-
data,” what protocols and standards will prevent this type of
breach from happening again? Who will be held accountable if an
unauthorized data breach undermines the narratives, identities,
and values of individuals whose DNA sequences become avail-
able for public knowledge or scrutiny? How can investigators and
research participants ensure that samples donated to research and
perhaps, governed strictly locally, do not become vulnerable once
they leave local jurisdictions?
LESSONS FROM HeLa
In 1950, Henrietta Lacks, an African-American woman, wife and
mother of five children, entered the public ward of Johns Hopkins
University complaining of a “knot on her womb” (Skloot, 2010).
Soon after, she was diagnosed with an aggressive form of cervi-
cal cancer that took her life less than a year later. Unbeknownst
to Lacks, however, a small part of her cancer tumor lived on.
As was common practice at the time, Lacks’ treating physician
collected her human cell tissue without her permission or knowl-
edge, labeled it “HeLa” using the initials of her first and last name,
and stored her specimens in a laboratory where he was endeavor-
ing unsuccessfully to grow an immortal line of cancer cells. For
the first time in the laboratory (and possibly in history), these
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cancer cells multiplied and survived, creating a durable line of
cell culture that the laboratory went on to share with anyone who
asked for them (Skloot, 2010).
Twenty-four years later, in 1974, the United States Congress
passed the National Research Act (NRA), which led to the pub-
lication of the Belmont Report (a foundational document in
biomedical research ethics) and the development of legal pro-
tections for human research participants engaging in federally
funded research (The National Commission for the Protection
of Human Subjects of Research, 1979; The Office for Human
Research Protection, 1991). The Common Rule requires that
researchers obtain informed consent to use the identifiable
research samples and data of patients and research participants,
or else that they de-identify the samples before sharing them. The
Belmont report requires that investigators respect participants in
research and treat them in an ethical manner by honoring their
autonomous decisions, protecting them from harm, and treat-
ing them justly and fairly. Today, it is clear that investigators
operating during Lacks’ life time lacked clear guidance on these
principles. Members of the public and research community, for
instance, have pointed to disrespect for Lacks’ private life and
autonomy, and the unjust enrichment of investigators who have
benefited from their research on the HeLa cells while her family
remained poor (Javitt, 2010; Skloot, 2010). While various schol-
ars in the humanities disciplines, including those funded by the
ethical, legal, and social issues (ELSI) in genetics program, have
worked diligently to identify and understand how to address ethi-
cal issues raised by genomic research, including those values at the
heart of the controversy around the use of the HeLa cells, there
remains much debate about how to best protect the privacy of
individuals who participate in genomic research.
Recent publication of Henrietta Lacks’ genome sequence on
the internet provides a case in point. Although the HeLa story has
caused a stir across the United States—leading to a public apology
by Johns Hopkins University to the Lacks family—Skloot’s publi-
cation did not dissuade researchers in Germany from publishing
her full genome earlier this year in 2013, again without prior con-
sent (Skloot, 2013). Researchers and journal editors, while still
following all rules, had seemingly overlooked any questions about
privacy and consent for the HeLa genome (National Institutes
of Health Advisory Committee to the Director HeLa Genome
Data Access Working Group, 2013). The public, however, was
not forgiving. The public posting evoked visceral reactions among
researchers, patient advocates, bioethicists andmembers of Lacks’
family who were concerned about the privacy implications for
Lacks and her descendants (National Institutes of Health Advisory
Committee to the Director HeLa Genome Data Access Working
Group, 2013). In response, the investigators removed Lack’s
genomic sequence from the public domain and other papers were
put on hold while the National Institutes of Health (NIH) initi-
ated a negotiation with the Lacks family (National Institutes of
Health Advisory Committee to the Director HeLa Genome Data
Access Working Group, 2013).
After a series of talks, NIH established the HeLa Genome
Data Access Working Group of the Advisory Committee to the
Director, which is a special committee charged with reviewing
the release of data from the HeLa Genome with input from
two serving members of the Lacks family (National Institutes of
Health Advisory Committee to the Director HeLa Genome Data
Access Working Group, 2013). These laudable efforts on the part
of leadership in the biomedical research community demonstrate
a swift and thoughtful response to the Lacks family’s disgruntle-
ment with the investigators’ failure to consult with them about
publicizing information that could reveal heritable traits and
information about Lacks and her descendants. They also demon-
strate the potential for public backlash against policies perceived
to be contrary to accepted ethical norms.
WHAT LEGACY WILL WE LEAVE FOR RESEARCH
PARTICIPANTS OF THIS GENERATION?
The expectations for researchers are rapidly changing. Consensus
is building among stakeholders, for instance, that research results
that can benefit participants and their families should be returned
to them, because of the important health and reproductive pre-
dispositions that genomic information may reveal (Henderson
et al., 2012). Some scholars have argued that there will be greater
demand among research participants who believe they have a
right to access the information in their genomes (Henderson
et al., 2008; McGuire et al., 2011). Research has also shown that
members of the public have privacy preferences that are out
of tune with long standing privacy policies applied to research
(McGuire et al., 2008, 2011; McGuire and Beskow, 2010; McGuire
and Lupski, 2010). Increasingly, participants are favoring more
restrictive data release/sharing options, and at higher rates—
in one study, nearly half (47%: McGuire et al., 2011) of the
participants selected to release their data on a restricted basis.
In addition, the general public is knowledgeable and con-
cerned about how genomic test results may affect future medical
treatment or insurance coverage. Although it is prohibited under
the Genetic Information Nondiscrimination Act for health insur-
ance groups to use genetic information to determine eligibility
and coverage, the confidentiality of such information remains a
concern for individuals, especially those living in underserved and
ethnically diverse communities (Goldenberg et al., 2013).
As exhibited by the research community’s response to the
public reaction to publication of the HeLa genome, privacy and
consent issues are likely to become predominant concerns in the
public psyche. An author at Slate Magazine, for instance, outlined
the questions that are likely on the minds of the readers of this
popular news source, “. . . the prevailing theme of Skloot’s book
is not on the question of how much Lacks and her family are
owed; rather, it’s that Lacks’ doctors experimented on and dis-
tributed her cells without asking, or telling, her or her family”
(Singer-Vine, 2010). Meanwhile a writer for Essence magazine
explained, “[t]he big thing with Henrietta’s cells is the privacy
violation. Her medical records were published at one point by a
journalist so there are these questions about her privacy. There are
also a lot of questions about whether you should take something
from somebody without asking” (Watts, 2012). As other countries
build their own genomic research laboratories and data collection
processes, it is becoming clear that the research community has an
opportunity here to build a legacy that will influence the public’s
opinion on research, data-sharing and informational privacy for
years to come.
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Currently, a solution that receives great support involves
including language in the consent form warning potential
research subjects that they will lose control and ownership over
their samples and data, and that reidentification is possible. In
addition, there are movements to educate the public about the
benefits of genomic research (Green et al., 2011). These mecha-
nisms, however, will not protect the family members of research
participants who are indirectly linked with research results, pre-
vent the stigmatization of communities and the community
members whose DNA samples were collected in one jurisdic-
tion and insufficiently secured in another, or adequately buffer
the damaging impact that high profile privacy breaches may have
on research. Community engagement helps to educate poten-
tial research subjects in a culturally competent manner about the
risks and benefits of participation in genetic research, but to be
truly effective, sound mechanisms that support fair negotiation
among researchers from different nations and that hold violators
accountable must be in place.
At the time of this publication, it will have been 81 years since
the Tuskegee Syphilis Study began in Tuskegee, Alabama and 41
years since it was terminated. Although egregious physical, men-
tal, and emotional research abuses like those that occurred at the
hands of the Public Health Service (PHS) have been outlawed,
many individuals remain skeptical of research. The Tuskegee
Syphilis Study, in particular, is often referenced as a reason for
why self-identified African-Americans are wary of participating in
biomedical research. The legacy of the PHS study remains indeli-
ble in the minds of many as one of the most infamous biomedical
research studies. What will research participants remember about
their participation in genetic research 50 years from today?
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